Scientific Industries Reports Decline in Q2 2025 Financial Performance

Scientific Industries, Inc. reported a decline in financial performance for the second quarter of 2025, with revenues of $2.33 million, a decrease of 12% from $2.65 million in the same period last year. For the first half of 2025, total revenues fell to $4.74 million, down 7.7% from $5.13 million in the first half of 2024. The company attributed this decline primarily to reduced sales in its Benchtop Laboratory Equipment Operations, particularly from the Genie brand, and delays in customer orders within its Bioprocessing Systems Operations. The gross profit margin also decreased, from 48.8% in Q2 2024 to 43.8% in Q2 2025, largely due to increased material costs driven by tariffs.

The company reported a net loss of $1.52 million for the three months ended June 30, 2025, compared to a loss of $1.28 million in the same quarter of the previous year. For the six-month period, the net loss was $3.30 million, slightly improved from a loss of $3.34 million in the prior year. Operating expenses decreased to $2.57 million in Q2 2025 from $2.63 million in Q2 2024, primarily due to reduced general and administrative costs following a workforce reduction in the Bioprocessing Systems segment.

In terms of strategic developments, Scientific Industries completed a private placement in April 2025, raising $1.55 million through the issuance of common stock and warrants. This capital infusion is expected to support ongoing operations and product development. The company also reported a significant organizational change, with a reduction in force in the Bioprocessing Systems Operations, which contributed to lower general and administrative expenses.

Operationally, the company’s total assets decreased to $10.23 million as of June 30, 2025, down from $11.56 million at the end of 2024. Current liabilities also saw a reduction, totaling $1.70 million compared to $1.75 million at the end of the previous fiscal year. The company’s cash and cash equivalents increased to $891,400, up from $587,900 at the end of 2024, reflecting improved cash management despite ongoing losses.

Looking ahead, Scientific Industries remains cautious about its outlook, citing ongoing challenges such as global trade uncertainties and reduced research funding impacting customer orders. The company is focused on enhancing its product offerings and operational efficiencies to navigate these challenges. The management emphasized the importance of strategic initiatives, including potential geographic expansion and product innovation, to drive future growth.